RAZUPROTAFIB
Razuprotafib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target receptor-type tyrosine-protein phosphatase beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | 1 | 2 | — | — | — | 2 |
| Edema | D004487 | — | R60.9 | 1 | 2 | — | — | — | 2 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 1 | 1 | — | — | — | 2 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | 1 | — | — | — | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | — | — | — | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | — | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | 1 | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RAZUPROTAFIB |
| INN | razuprotafib |
| Description | Razuprotafib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target receptor-type tyrosine-protein phosphatase beta. |
| Classification | Small molecule |
| Drug class | protein tyrosine phosphatase 1B inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(=O)(=O)O)cc1)c1csc(-c2cccs2)n1 |
Identifiers
| PDB | — |
| CAS-ID | 1008510-37-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3931971 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 0WAX4UT396 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
PTPRB
PTPRB
Organism
Homo sapiens
Gene name
PTPRB
Gene synonyms
PTPB
NCBI Gene ID
Protein name
receptor-type tyrosine-protein phosphatase beta
Protein synonyms
protein tyrosine phosphatase, receptor type, beta polypeptide, Vascular endothelial protein tyrosine phosphatase, VE-PTP
Uniprot ID
Mouse ortholog
Ptprb (19263)
receptor-type tyrosine-protein phosphatase beta (Q8CIW2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 56 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use